Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Opposing Dynamics of CD4 + Regulatory and CD8 + Foxp3+ T Cells Characterize Immune Imbalance in Rheumatoid Arthritis.

Inflammation·2026
Same author

DNMT3A-driven Clonal Expansion of Hematopoiesis Influences Autoimmunity Mediated by Distinct Immune Cell Populations: A Mendelian Randomization Study.

Combinatorial chemistry & high throughput screening·2026
Same author

Discovery of biomarkers for primary Sj ögren's syndrome based on multi-omics data, construction of diagnostic models, and clinical correlation analysis.

Arthritis research & therapy·2026
Same author

Soluble IL-2 receptor and memory Treg profiles differentiate early rheumatoid arthritis from undifferentiated arthritis at initial presentation.

Frontiers in immunology·2026
Same author

Engineering human synovial organoids as predictive ecosystems for disease modeling and therapeutic response in rheumatology.

Current opinion in immunology·2026
Same author

Experiment and Modelling of Ultrasonic Vibration-Assisted Creep-Aging Tensile for 7055-T6 Alloy.

Materials (Basel, Switzerland)·2026

相关实验视频

Updated: May 11, 2026

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

11.3K

用于缓慢控制释放系统的Lambda-Cyhalothrin微囊的制备,表征和生物活性评估.

Liying Wang1, Juan Liu1, Chong Gao1

  • 1Institute of Functional Molecules, Shenyang University of Chemical Technology, Shenyang 110142, China.

ACS omega
|February 26, 2024
PubMed
概括

新的聚尿素微囊可以改善农药的输送. 这些装有兰巴-甲的微囊提供了增强的疗效和延长的受控释放,减少对环境的影响.

科学领域:

  • 聚合物化学 聚合物化学
  • 材料科学 材料科学 材料科学
  • 农业化学 农业化学

背景情况:

  • 接口聚合使可控制释放的微囊,提高杀虫剂的有效性和减少环境污染.
  • 聚尿素微囊是有效的封装活性成分缓释应用.

研究的目的:

  • 通过界面聚合,制备和描述装载着兰巴-甲的聚尿素微囊.
  • 调查开发的微囊的受控释放特性和生物活性.

主要方法:

  • 使用改性异酸盐 (MDI) 和GT-34启动器进行界面聚合.
  • 通过光学显微镜,扫描电子显微镜,FTIR和热重力测量分析进行表征.
  • 在不同的pH,温度和MDI度下进行体外释放研究;对Myzus persicae进行生物活性测定.

主要成果:

  • 成功合成了具有平均尺寸为1.97微米和91.48%封装效率的聚尿素微囊.
  • 在不同的条件下,在乙二溶液中表现出持续释放 (>7天) 和一致的释放概况.
  • 对Myzus persicae的持续时间超过21天,优于可乳化缩配方.

结论:

  • 通过界面聚合制备的聚尿素微囊为lambda-cyhalothrin提供了出色的持续释放和增强的生物疗效.

更多相关视频

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins
00:11

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Published on: August 31, 2019

23.8K
Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches
10:07

Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches

Published on: October 8, 2021

1.4K

相关实验视频

Last Updated: May 11, 2026

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

11.3K
Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins
00:11

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Published on: August 31, 2019

23.8K
Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches
10:07

Preparation of Multifunctional Silk-Based Microcapsules Loaded with DNA Plasmids Encoding RNA Aptamers and Riboswitches

Published on: October 8, 2021

1.4K
  • 控制释放机制遵循一级运动模型,主要由Fickian扩散驱动.
  • 这些微囊代表了改善农药性能和环境安全的有希望的配方.